Zymeworks BC Inc
Zymeworks BC Inc (ZYME) Straddle
ZYME straddle scan found 15 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 43.6%.
Read more
Trading a ZYME straddle lets you take a pure volatility position on Zymeworks BC Inc without committing to a direction. Zymeworks BC Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate ZYME straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on ZYME profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Zymeworks BC Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the ZYME straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc.
It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the ZYME straddle is the cleanest expression of that view. Our scanner prices every ZYME straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a ZYME straddle into a catalyst or short a ZYME straddle to harvest decay, the options straddle setups that matter are all in one place.
| Dec 17, 2027 | 45.00 | $21.65 | 455 | 0% | 43.6% | $66.65 | $23.35 | 0 |
| Dec 17, 2027 | 40.00 | $18.00 | 455 | 0% | 39.9% | $58.00 | $22.00 | 0 |
| Oct 16, 2026 | 30.00 | $4.40 | 28 | 0% | 38.2% | $34.40 | $25.60 | 31 |
| Apr 16, 2027 | 35.00 | $11.70 | 210 | 0% | 37.7% | $46.70 | $23.30 | 0 |
| Dec 17, 2027 | 35.00 | $15.00 | 455 | 0% | 35.0% | $50.00 | $20.00 | 0 |
| Apr 16, 2027 | 30.00 | $9.23 | 210 | 0% | 30.4% | $39.23 | $20.78 | 5 |
| Dec 17, 2027 | 30.00 | $13.00 | 455 | 0% | 29.0% | $43.00 | $17.00 | 9 |
| Apr 16, 2027 | 22.50 | $9.40 | 210 | 0% | 25.5% | $31.90 | $13.10 | 0 |
| Dec 17, 2027 | 25.00 | $12.00 | 455 | 0% | 25.5% | $37.00 | $13.00 | 0 |
| Dec 17, 2027 | 22.50 | $12.50 | 455 | 0% | 24.6% | $35.00 | $10.00 | 0 |
As of September 23, 2026
Find the right straddle before volatility moves
Track ZYME straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→